# Aerosolized Aldesleukin in Treating Patients With Lung Metastases

> **NCT01590069** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 70 (estimated)

## Conditions studied

- Metastatic Malignant Neoplasm in the Lung
- Metastatic Melanoma
- Metastatic Osteosarcoma
- Metastatic Renal Cell Cancer
- Sarcoma
- Stage IV Cutaneous Melanoma AJCC v6 and v7
- Stage IV Osteosarcoma AJCC v7
- Stage IV Renal Cell Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Aerosolized Aldesleukin
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01590069
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2012-06-28
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01590069

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01590069, "Aerosolized Aldesleukin in Treating Patients With Lung Metastases". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01590069. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*